F-18 FDG uptake in endometrial cancer
1HIMEDIC Imaging Center at Lake Yamanaka, Japan.
Clinical Nuclear Medicine
|January 4, 2001
Summary
Positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG) successfully detected endometrial cancer in a 60-year-old woman. The imaging also identified lung metastases, later confirmed by biopsy and CT scans.
Area of Science:
- Gynecologic Oncology
- Nuclear Medicine Imaging
- Medical Diagnostics
Background:
- Endometrial cancer is a prevalent gynecologic malignancy.
- Early and accurate detection is crucial for effective treatment.
- Positron emission tomography (PET) is an advanced imaging modality.
Purpose of the Study:
- To evaluate the utility of F-18 fluorodeoxyglucose (FDG) PET in detecting endometrial cancer.
- To assess the capability of FDG PET in identifying distant metastases from endometrial cancer.
Main Methods:
- A 60-year-old woman presenting with abdominal distention underwent F-18 FDG PET imaging.
- Findings from FDG PET were correlated with endometrial biopsy and chest computed tomography (CT).
Main Results:
- FDG PET revealed heterogeneous and marked accumulation in the endometrium, indicative of endometrial cancer.
- Focal intense FDG accumulation in both lungs suggested lung metastases.
- Endometrial biopsy confirmed endometrial cancer, and chest CT confirmed lung metastases.
Conclusions:
- F-18 FDG PET is a valuable tool for detecting endometrial cancer.
- FDG PET can effectively identify lung metastases in patients with endometrial cancer.
- Integrated imaging and biopsy approaches ensure accurate diagnosis and staging.
